Table 4.
CIN3/AIS per 100000 Women and Per 100000 Estimated Screened Women at 5 Sites
| Age Group (Years) | Years | N CIN3/ AIS | Population Denominator | CIN3/AIS per 100000 Women per Year | Screening Denominator | CIN3/AIS per 100000 Screened Women per Year | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rate | IRR | 95% CI | aIRR | 95% CI | Rate | IRR | 95% CI | aIRR | 95% CI | |||||
| 18–20 | 2008–2009 | 71 | 165 606 | 42.9 | 1.00 | 1.00 | 50 241 | 141.3 | 1.00 | 1.00 | ||||
| 2010–2011 | 26 | 168 137 | 15.5 | 0.36 | (0.23–0.57) | 0.36 | (0.23–0.56) | 24 431 | 106.4 | 0.75 | (0.48–1.18) | 0.72 | (0.46–1.14) | |
| 2012–2013 | 7 | 165 633 | 4.2 | 0.10 | (0.05–0.21) | 0.10 | (0.04–0.21) | 11 680 | 59.9 | 0.42 | (0.20–0.92) | 0.42 | (0.19–0.92) | |
| 2014–2015 | 6 | 160 356 | 3.7 | 0.09 | (0.04–0.20) | 0.09 | (0.04–0.20) | 6 876 | 87.3 | 0.62 | (0.27–1.42) | 0.67 | (0.29–1.56) | |
| 21–24 | 2008–2009 | 333 | 219 635 | 151.6 | 1.00 | 1.00 | 104 508 | 318.6 | 1.00 | 1.00 | ||||
| 2010–2011 | 253 | 227 592 | 111.2 | 0.73 | (0.62–0.86) | 0.74 | (0.63–0.87) | 90 777 | 278.7 | 0.87 | (0.74–1.03) | 0.88 | (0.75–1.04) | |
| 2012–2013 | 199 | 228 828 | 87.0 | 0.57 | (0.48–0.68) | 0.58 | (0.49–0.69) | 80 775 | 246.4 | 0.77 | (0.65–0.92) | 0.78 | (0.66–0.93) | |
| 2014–2015 | 118 | 226 382 | 52.1 | 0.34 | (0.28–0.42) | 0.35 | (0.28–0.43) | 67 882 | 173.8 | 0.55 | (0.44–0.67) | 0.57 | (0.46–0.70) | |
| 25–29 | 2008–2009 | 528 | 290 829 | 181.6 | 1.00 | 1.00 | 144 416 | 365.6 | 1.00 | 1.00 | ||||
| 2010–2011 | 483 | 297 502 | 162.4 | 0.89 | (0.79–1.01) | 0.89 | (0.79–1.01) | 127 612 | 378.5 | 1.04 | (0.92–1.17) | 1.03 | (0.91–1.16) | |
| 2012–2013 | 510 | 309 893 | 164.6 | 0.91 | (0.80–1.02) | 0.91 | (0.80–1.02) | 119 124 | 428.1 | 1.17 | (1.04–1.32) | 1.19 | (1.05–1.34) | |
| 2014–2015 | 428 | 324 780 | 131.8 | 0.73 | (0.64–0.82) | 0.73 | (0.64–0.83) | 110 344 | 387.9 | 1.06 | (0.93–1.21) | 1.12 | (0.98–1.27) | |
| 30–34 | 2008–2009 | 357 | 261 881 | 136.3 | 1.00 | 1.00 | 118 701 | 301.6 | 1.00 | 1.00 | ||||
| 2010–2011 | 362 | 273 774 | 132.2 | 0.97 | (0.84–1.12) | 0.97 | (0.84–1.12) | 109 585 | 332.2 | 1.10 | (0.95–1.27) | 1.10 | (0.95–1.27) | |
| 2012–2013 | 365 | 289 619 | 126.0 | 0.92 | (0.80–1.07) | 0.93 | (0.80–1.07) | 106 319 | 343.3 | 1.14 | (0.99–1.32) | 1.16 | (1.00–1.34) | |
| 2014–2015 | 446 | 299 793 | 148.8 | 1.09 | (0.95–1.25) | 1.09 | (0.95–1.26) | 99 249 | 449.4 | 1.49 | (1.30–1.72) | 1.55 | (1.35–1.79) | |
| 35–39 | 2008–2009 | 226 | 261 930 | 86.3 | 1.00 | 1.00 | 109 161 | 207.0 | 1.00 | 1.00 | ||||
| 2010–2011 | 256 | 252 769 | 101.3 | 1.17 | (0.98–1.40) | 1.17 | (0.98–1.40) | 91 635 | 279.4 | 1.35 | (1.13–1.61) | 1.33 | (1.11–1.59) | |
| 2012–2013 | 213 | 254 749 | 83.6 | 0.97 | (0.80–1.17) | 0.97 | (0.80–1.17) | 86 877 | 245.2 | 1.18 | (0.98–1.43) | 1.19 | (0.99–1.44) | |
| 2014–2015 | 212 | 267 513 | 79.2 | 0.92 | (0.76–1.11) | 0.92 | (0.76–1.11) | 78 266 | 269.6 | 1.31 | (1.08–1.58) | 1.34 | (1.11–1.61) | |
All data are from the Human Papillomavirus Vaccine Impact Monitoring Project (HPV-IMPACT), 2008–2015. All aIRRs were adjusted for surveillance site. Bolded values denote statistical significance. Population denominator is the sum of the number of women in the catchment areas for each of the two years. Screening denominator is the sum of the estimated number of screened women in the catchment areas for each of the two years.
Abbreviations: aIRR, adjusted incidence rate ratio; AIS, adenocarcinoma in situ; CI, confidence interval; CIN3, cervical intraepithelial neoplasia grade 3; IRR, incidence rate ratio.